Factors related to the outcome of prophylactic platelet transfusions in patients with hematologic malignancies: an observational study

Abstract

Transfusion outcomes were significantly related to several PC-related factors. Associations for ABO matching status and storage duration were stronger than previously reported. Taking into account such factors when selecting a PC for transfusion could be beneficial to the recipient.

Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis

“…Major mismatched platelet transfusions promote clearance of transfused platelets, lowering the CCI, 7–9 decreasing the efficacy of the transfusion, and shortening the time for a subsequent platelet transfusion, thus increasing the demand for platelet transfusions. Two previous studies 7,8 found a 4–5 h decrease in the platelet transfusion interval for those who received an ABO major mismatched platelet transfusion.…”

“…Major mismatched platelet transfusions promote clearance of transfused platelets, lowering the CCI, 7–9 decreasing the efficacy of the transfusion, and shortening the time for a subsequent platelet transfusion, thus increasing the demand for platelet transfusions. Two previous studies 7,8 found a 4–5 h decrease in the platelet transfusion interval for those who received an ABO major mismatched platelet transfusion. Similarly, we found an increased requirement for a subsequent platelet transfusion for recipients of a major mismatched platelet transfusion with 20% increased odds of receiving another platelet transfusion within 2 days.…”

“…Trends toward increased mortality were associated with ABO non‐identical platelet transfusions in cardiac surgery patients 3 and acute promyelocytic leukemia (APL) patients 4 and ABO incompatible (major mismatched) platelet transfusions in intracerebral hemorrhage (ICH) patients 5 . ABO major mismatched platelets are associated with decreased patient peripheral blood platelet count increment 6–10 . Additionally, although reactions are rare, minor mismatched platelet transfusions are the most common cause of acute hemolytic reactions 11 and have been associated with fatal outcomes 11–14 …”

“…5 ABO major mismatched platelets are associated with decreased patient peripheral blood platelet count increment. [6][7][8][9][10] Additionally, although reactions are rare, minor mismatched platelet transfusions are the most common cause of acute hemolytic reactions 11 and have been associated with fatal outcomes. [11][12][13][14] The Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) public use donor-recipient linked database contains information about blood donors, components, and recipients of transfused blood products at 12 hospitals served by four blood centers in the United States.…”

No increase in anti‐A isohemagglutinin titer after SARS‐CoV‐2 infection: A retrospective cohort analysis of group O apheresis platelet donors

“…Although transfusion of ABO-identical platelet concentrate (PC) is widely recognized as the most effective and safest therapeutic strategy its widespread use is not always possible. 1 For this reason, a vast majority of blood banks enable the transfusion of non-identical PCs, especially the ones obtained through apheresis from group O donors to non-O recipients. Such PCs pose a risk of posttransfusion hemolytic reaction, which may be especially intense in group A recipients.…”